Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion

Claudio Tripodo, Sabina Sangaletti, Carla Guarnotta, Pier P. Piccaluga, Matilde Cacciatore, Michela Giuliano, Giovanni Franco, Claudia Chiodoni, Marika Sciandra, Silvia Miotti, Giuseppe Calvaruso, Alessandra Carè, Ada M. Florena, Katia Scotlandi, Attilio Orazi, Stefano A. Pileri, Mario P. Colombo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In myeloid malignancies, the neoplastic clone outgrows normal hematopoietic cells toward BM failure. This event is also sustained by detrimental stromal changes, such as BM fibrosis and osteosclerosis, whose occurrence is harbinger of a dismal prognosis. We show that the matricellular protein SPARC contributes to the BM stromal response to myeloproliferation. The degree of SPARC expression in BM stromal elements, including CD146+ mesenchymal stromal cells, correlates with the degree of stromal changes, and the severity of BM failure characterizing the prototypical myeloproliferative neoplasm primary myelofibrosis. Using Sparc-/- mice and BM chimeras, we demonstrate that SPARC contributes to the development of significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis. We found that SPARC deficiency in the radioresistant BM stroma compartment impairs myelofibrosis but, at the same time, associates with an enhanced reactive myeloproliferative response to thrombopoietin. The link betwen SPARC stromal deficiency and enhanced myeloid cell expansion under a myeloproliferative spur is also supported by the myeloproliferative phenotype resulting from the transplantation of defective Apcmin mutant hematopoietic cells into Sparc-/- but not WT recipient BM stroma. Our results highlight a complex influence of SPARC over the stromal and hematopoietic BM response in myeloproliferative conditions.

Original languageEnglish
Pages (from-to)3541-3554
Number of pages14
JournalBlood
Volume120
Issue number17
DOIs
Publication statusPublished - Oct 25 2012

Fingerprint

Thrombopoietin
Primary Myelofibrosis
Myeloid Cells
Fibrosis
Osteosclerosis
Mesenchymal Stromal Cells
Neoplasms
Clone Cells
Transplantation
Phenotype
Proteins

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. / Tripodo, Claudio; Sangaletti, Sabina; Guarnotta, Carla; Piccaluga, Pier P.; Cacciatore, Matilde; Giuliano, Michela; Franco, Giovanni; Chiodoni, Claudia; Sciandra, Marika; Miotti, Silvia; Calvaruso, Giuseppe; Carè, Alessandra; Florena, Ada M.; Scotlandi, Katia; Orazi, Attilio; Pileri, Stefano A.; Colombo, Mario P.

In: Blood, Vol. 120, No. 17, 25.10.2012, p. 3541-3554.

Research output: Contribution to journalArticle

Tripodo, C, Sangaletti, S, Guarnotta, C, Piccaluga, PP, Cacciatore, M, Giuliano, M, Franco, G, Chiodoni, C, Sciandra, M, Miotti, S, Calvaruso, G, Carè, A, Florena, AM, Scotlandi, K, Orazi, A, Pileri, SA & Colombo, MP 2012, 'Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion', Blood, vol. 120, no. 17, pp. 3541-3554. https://doi.org/10.1182/blood-2011-12-398537
Tripodo, Claudio ; Sangaletti, Sabina ; Guarnotta, Carla ; Piccaluga, Pier P. ; Cacciatore, Matilde ; Giuliano, Michela ; Franco, Giovanni ; Chiodoni, Claudia ; Sciandra, Marika ; Miotti, Silvia ; Calvaruso, Giuseppe ; Carè, Alessandra ; Florena, Ada M. ; Scotlandi, Katia ; Orazi, Attilio ; Pileri, Stefano A. ; Colombo, Mario P. / Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. In: Blood. 2012 ; Vol. 120, No. 17. pp. 3541-3554.
@article{8aaf60ab3b6441e7b0883e9071c3acef,
title = "Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion",
abstract = "In myeloid malignancies, the neoplastic clone outgrows normal hematopoietic cells toward BM failure. This event is also sustained by detrimental stromal changes, such as BM fibrosis and osteosclerosis, whose occurrence is harbinger of a dismal prognosis. We show that the matricellular protein SPARC contributes to the BM stromal response to myeloproliferation. The degree of SPARC expression in BM stromal elements, including CD146+ mesenchymal stromal cells, correlates with the degree of stromal changes, and the severity of BM failure characterizing the prototypical myeloproliferative neoplasm primary myelofibrosis. Using Sparc-/- mice and BM chimeras, we demonstrate that SPARC contributes to the development of significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis. We found that SPARC deficiency in the radioresistant BM stroma compartment impairs myelofibrosis but, at the same time, associates with an enhanced reactive myeloproliferative response to thrombopoietin. The link betwen SPARC stromal deficiency and enhanced myeloid cell expansion under a myeloproliferative spur is also supported by the myeloproliferative phenotype resulting from the transplantation of defective Apcmin mutant hematopoietic cells into Sparc-/- but not WT recipient BM stroma. Our results highlight a complex influence of SPARC over the stromal and hematopoietic BM response in myeloproliferative conditions.",
author = "Claudio Tripodo and Sabina Sangaletti and Carla Guarnotta and Piccaluga, {Pier P.} and Matilde Cacciatore and Michela Giuliano and Giovanni Franco and Claudia Chiodoni and Marika Sciandra and Silvia Miotti and Giuseppe Calvaruso and Alessandra Car{\`e} and Florena, {Ada M.} and Katia Scotlandi and Attilio Orazi and Pileri, {Stefano A.} and Colombo, {Mario P.}",
year = "2012",
month = "10",
day = "25",
doi = "10.1182/blood-2011-12-398537",
language = "English",
volume = "120",
pages = "3541--3554",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion

AU - Tripodo, Claudio

AU - Sangaletti, Sabina

AU - Guarnotta, Carla

AU - Piccaluga, Pier P.

AU - Cacciatore, Matilde

AU - Giuliano, Michela

AU - Franco, Giovanni

AU - Chiodoni, Claudia

AU - Sciandra, Marika

AU - Miotti, Silvia

AU - Calvaruso, Giuseppe

AU - Carè, Alessandra

AU - Florena, Ada M.

AU - Scotlandi, Katia

AU - Orazi, Attilio

AU - Pileri, Stefano A.

AU - Colombo, Mario P.

PY - 2012/10/25

Y1 - 2012/10/25

N2 - In myeloid malignancies, the neoplastic clone outgrows normal hematopoietic cells toward BM failure. This event is also sustained by detrimental stromal changes, such as BM fibrosis and osteosclerosis, whose occurrence is harbinger of a dismal prognosis. We show that the matricellular protein SPARC contributes to the BM stromal response to myeloproliferation. The degree of SPARC expression in BM stromal elements, including CD146+ mesenchymal stromal cells, correlates with the degree of stromal changes, and the severity of BM failure characterizing the prototypical myeloproliferative neoplasm primary myelofibrosis. Using Sparc-/- mice and BM chimeras, we demonstrate that SPARC contributes to the development of significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis. We found that SPARC deficiency in the radioresistant BM stroma compartment impairs myelofibrosis but, at the same time, associates with an enhanced reactive myeloproliferative response to thrombopoietin. The link betwen SPARC stromal deficiency and enhanced myeloid cell expansion under a myeloproliferative spur is also supported by the myeloproliferative phenotype resulting from the transplantation of defective Apcmin mutant hematopoietic cells into Sparc-/- but not WT recipient BM stroma. Our results highlight a complex influence of SPARC over the stromal and hematopoietic BM response in myeloproliferative conditions.

AB - In myeloid malignancies, the neoplastic clone outgrows normal hematopoietic cells toward BM failure. This event is also sustained by detrimental stromal changes, such as BM fibrosis and osteosclerosis, whose occurrence is harbinger of a dismal prognosis. We show that the matricellular protein SPARC contributes to the BM stromal response to myeloproliferation. The degree of SPARC expression in BM stromal elements, including CD146+ mesenchymal stromal cells, correlates with the degree of stromal changes, and the severity of BM failure characterizing the prototypical myeloproliferative neoplasm primary myelofibrosis. Using Sparc-/- mice and BM chimeras, we demonstrate that SPARC contributes to the development of significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis. We found that SPARC deficiency in the radioresistant BM stroma compartment impairs myelofibrosis but, at the same time, associates with an enhanced reactive myeloproliferative response to thrombopoietin. The link betwen SPARC stromal deficiency and enhanced myeloid cell expansion under a myeloproliferative spur is also supported by the myeloproliferative phenotype resulting from the transplantation of defective Apcmin mutant hematopoietic cells into Sparc-/- but not WT recipient BM stroma. Our results highlight a complex influence of SPARC over the stromal and hematopoietic BM response in myeloproliferative conditions.

UR - http://www.scopus.com/inward/record.url?scp=84868582302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868582302&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-12-398537

DO - 10.1182/blood-2011-12-398537

M3 - Article

VL - 120

SP - 3541

EP - 3554

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -